Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) hit a new 52-week high during trading on Thursday . The stock traded as high as $127.16 and last traded at $125.57, with a volume of 473,402 shares trading hands. The stock had previously closed at $126.49.

A number of analysts have recently issued reports on ZBH shares. Goldman Sachs Group Inc. dropped their price target on shares of Zimmer Biomet Holdings from $113.00 to $111.00 in a report on Friday, April 8th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Morgan Stanley reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Barclays PLC reaffirmed a “buy” rating on shares of Zimmer Biomet Holdings in a report on Saturday, April 30th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 price target on shares of Zimmer Biomet Holdings in a report on Thursday, April 28th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $124.95.

The stock has a market capitalization of $24.95 billion and a P/E ratio of 308.42. The company has a 50-day moving average of $120.82 and a 200-day moving average of $109.79.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its earnings results on Thursday, April 28th. The company reported $2.00 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.07. The firm had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.88 billion. The business’s revenue was up 67.8% compared to the same quarter last year. During the same quarter last year, the business earned $1.54 earnings per share. On average, equities research analysts anticipate that Zimmer Biomet Holdings Inc. will post $7.96 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Friday, June 24th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Wednesday, June 22nd.

In other Zimmer Biomet Holdings news, CAO Tony W. Collins sold 3,611 shares of the stock in a transaction dated Tuesday, June 14th. The stock was sold at an average price of $116.43, for a total value of $420,428.73. Following the sale, the chief accounting officer now owns 3,245 shares of the company’s stock, valued at approximately $377,815.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniel P. Florin sold 15,000 shares of the stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $124.98, for a total value of $1,874,700.00. Following the completion of the sale, the chief financial officer now directly owns 16,983 shares in the company, valued at approximately $2,122,535.34. The disclosure for this sale can be found here.

A number of large investors recently bought and sold shares of ZBH. Vanguard Group Inc. bought a new stake in Zimmer Biomet Holdings during the fourth quarter worth about $1,006,696,000. Eaton Vance Management bought a new stake in Zimmer Biomet Holdings during the fourth quarter worth about $86,854,000. Jennison Associates LLC bought a new stake in Zimmer Biomet Holdings during the fourth quarter worth about $71,968,000. Levin Capital Strategies L.P. bought a new stake in Zimmer Biomet Holdings during the fourth quarter worth about $69,610,000. Finally, Wells Fargo & Company MN bought a new stake in Zimmer Biomet Holdings during the fourth quarter worth about $66,348,000.

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.